AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (601.2 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Preoperative ultrasound combined with routine blood tests in predicting the malignant risk of pancreatic cystic neoplasms

Xiuchao Wang1,*Junjin Wang1,*Xi Wei2Lihui Zhao2Bo Ni1Zekun Li1Chuntao Gao1Song Gao1Tiansuo Zhao1Jian Wang1Weidong Ma1Xiao Hu3 ( )Jihui Hao1 ( )
Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
Department of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao 266000, China

*These authors contributed equally to this work.

Show Author Information

Abstract

Objective

Accurate preoperative identification of benign or malignant pancreatic cystic neoplasms (PCN) may help clinicians make better intervention choices and will be essential for individualized treatment.

Methods

Preoperative ultrasound and laboratory examination findings, and demographic characteristics were collected from patients. Multiple logistic regression was used to identify independent risk factors associated with malignant PCN, which were then included in the nomogram and validated with an external cohort. The Net Reclassification Index (NRI) and Integrated Discrimination Improvement (IDI) were calculated to evaluate the improvement in the predictive power of the new model with respect to that of a combined imaging and tumor marker prediction model.

Results

Malignant PCN were found in 83 (40.7%) and 33 (38.7%) of the model and validation cohorts, respectively. Multivariate analysis identified age, tumor location, imaging of tumor boundary, blood type, mean hemoglobin concentration, neutrophil-to-lymphocyte ratio, carbohydrate antigen 19-9, and carcinoembryonic antigen as independent risk factors for malignant PCN. The calibration curve indicated that the predictions based on the nomogram were in excellent agreement with the actual observations. A nomogram score cutoff of 192.5 classified patients as having low vs. high risk of malignant PCN. The model achieved good C-statistics of 0.929 (95% CI 0.890–0.968, P < 0.05) and 0.951 (95% CI 0.903–0.998, P < 0.05) in predicting malignancy in the development and validation cohorts, respectively. NRI = 0.268; IDI = 0.271 (P < 0.001 for improvement). The DCA curve indicated that our model yielded greater clinical benefits than the comparator model.

Conclusions

The nomogram showed excellent performance in predicting malignant PCN and may help surgeons select patients for detailed examination and surgery. The nomogram is freely available at https://wangjunjinnomogram.shinyapps.io/DynNomapp/.

Electronic Supplementary Material

Download File(s)
cbm-19-10-1503_ESM.pdf (4.9 MB)

References

1

Kromrey ML, Bülow R, Hübner J, Paperlein C, Lerch MM, Ittermann T, et al. Prospective study on the incidence, prevalence and 5-year pancreatic-related mortality of pancreatic cysts in a population-based study. Gut. 2018; 67: 138-45.

2

Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020; 76: 182-8.

3
Basturk O, Reid MD, Adsay NV. Pathologic Classification and Biological Behavior of Pancreatic Neoplasia. In Neoptolemos JP, Urrutia R, Abbruzzese J, Büchler MW (eds): Pancreatic Cancer. New York, NY: Springer New York. 2017; 1-37.
4

Ayoub F, Davis AM, Chapman CG. Pancreatic Cysts-An Overview and Summary of Society Guidelines, 2021. JAMA. 2021; 325: 391-2.

5

Jones MJ, Buchanan AS, Neal CP, Dennison AR, Metcalfe MS, Garcea G. Imaging of indeterminate pancreatic cystic lesions: a systematic review. Pancreatology. 2013; 13: 436-42.

6

Singhi AD, McGrath K, Brand RE, Khalid A, Zeh HJ, Chennat JS, et al. Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia. Gut. 2018; 67: 2131-41.

7

Asaoka T, Miyamoto A, Maeda S, Tsujie M, Hama N, Yamamoto K, et al. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer. Pancreatology. 2016; 16: 434-40.

8

Chen Y, Yan H, Wang Y, Shi Y, Dai G. Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma. Sci Rep. 2017; 7: 753.

9

Kumarasamy C, Sabarimurugan S, Madurantakam RM, Lakhotiya K, Samiappan S, Baxi S, et al. Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer-A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2019; 98: e14834.

10

Goh BKP, Tan DMY, Chan CY, Lee SY, Lee VTW, Thng CH, et al. Are preoperative blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios useful in predicting malignancy in surgically-treated mucin-producing pancreatic cystic neoplasms? J Surg Oncol. 2015; 112: 366-71.

11

Gao X, Pan Y, Han W, Hu C, Wang C, Chen L, et al. Association of systemic inflammation and body mass index with survival in patients with resectable gastric or gastroesophageal junction adenocarcinomas. Cancer Biol Med. 2021; 18: 283-97.

12

Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, BottsfordMiller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012; 366: 610-8.

13

Li X, Xu H, Gao P. ABO blood group and diabetes mellitus influence the risk for pancreatic cancer in a population from China. Med Sci Monit. 2018; 24: 9392-8.

14

Iodice S, Maisonneuve P, Botteri E, Sandri MT, Lowenfels AB. ABO blood group and cancer. Eur J Cancer. 2010; 46: 3345-50.

15

Kimura W, Moriya T, Hirai I, Hanada K, Abe H, Yanagisawa A, et al. Multicenter study of serous cystic neoplasm of the Japan pancreas society. Pancreas. 2012; 41: 380-7.

16

Chu LC, Singhi AD, Haroun RR, Hruban RH, Fishman EK. The many faces of pancreatic serous cystadenoma: Radiologic and pathologic correlation. Diagn Interv Imaging. 2017; 98: 191-202.

17

Chen F, Liang JY, Zhao QY, Wang LY, Li J, Deng Z, et al. Differentiation of branch duct intraductal papillary mucinous neoplasms from serous cystadenomas of the pancreas using contrast-enhanced sonography. J Ultrasound Med. 2014; 33: 449-55.

18

Vege SS, Ziring B, Jain R, Moayyedi P. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015; 148: 819-22; quize12-3.

19

Scheiman JM, Hwang JH, Moayyedi P. American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015; 148: 824-48.e22.

20

Tanaka M, Fernández-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017; 17: 738-53.

21

European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018; 67: 789-804.

22

Morelli L, Guadagni S, Borrelli V, Pisano R, Di Franco G, Palmeri M, et al. Role of abdominal ultrasound for the surveillance follow-up of pancreatic cystic neoplasms: a cost-effective safe alternative to the routine use of magnetic resonance imaging. World J Gastroenterol. 2019; 25: 2217-28.

23

Wang W, Zhang L, Chen L, Wei J, Sun Q, Xie Q, et al. Serum carcinoembryonic antigen and carbohydrate antigen 19-9 for prediction of malignancy and invasiveness in intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Biomed Rep. 2015; 3: 43-50.

24

Carmicheal J, Patel A, Dalal V, Atri P, Dhaliwal AS, Wittel UA, et al. Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s). Biochim Biophys Acta Rev Cancer. 2020; 1873: 188318.

25

Kern SE, Hruban RH, Hidalgo M, Yeo CJ. An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. Cancer Biol Ther. 2002; 1: 607-13.

26

Nougaret S, Mannelli L, Pierredon MA, Schembri V, Guiu B. Cystic pancreatic lesions: from increased diagnosis rate to new dilemmas. Diagn Interv Imaging. 2016; 97: 1275-85.

27

Farrell JJ. Prevalence, diagnosis and management of pancreatic cystic neoplasms: current status and future directions. Gut Liver. 2015; 9: 571-89.

28

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420: 860-7.

29

Lan C, Li X, Wang X, Hao J, Ren H. A new combined criterion to better predict malignant lesions in patients with pancreatic cystic neoplasms. Cancer Biol Med. 2018; 15: 70-8.

30

Wolpin BM, Chan AT, Hartge P, Chanock SJ, Kraft P, Hunter DJ, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 2009; 101: 424-31.

31

Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009; 41: 986-90.

32

Hofmann BT, Stehr A, Dohrmann T, Güngör C, Herich L, Hiller J, et al. ABO blood group IgM isoagglutinins interact with tumor-associated O-glycan structures in pancreatic cancer. Clin Cancer Res. 2014; 20: 6117-26.

33

Tuppy H, Staudenbauer WL. Microsomal incorporation of N-acetyl-D-galactosamine into blood group substance. Nature. 1966; 210: 316-7.

34

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140: 883-99.

35

Dall’olio F. Protein glycosylation in cancer biology: an overview. Clin Mol Pathol. 1996; 49: M126-35.

36

Bhattathiri VN. Relation of erythrocyte and iron indices to oral cancer growth. Radiother Oncol. 2001; 59: 221-6.

37

Sheng X, Chen W, Xu Y, Lin F, Cao H. Higher mean corpuscular hemoglobin concentration is associated with worse prognosis of hepatorenal syndrome: a multicenter retrospective study. Am J Med Sci. 2022; 363: 25-32.

38

Adris N, Chua ACG, Knuiman MW, Divitini ML, Trinder D, Olynyk JK, et al. A prospective cohort examination of haematological parameters in relation to cancer death and incidence: the Busselton Health Study. BMC Cancer. 2018; 18: 863.

39

Tsantes AE, Bonovas S, Travlou A, Sitaras NM. Redox imbalance, macrocytosis, and RBC homeostasis. Antioxid Redox Signal. 2006; 8: 1205-16.

Cancer Biology & Medicine
Pages 1503-1516
Cite this article:
Wang X, Wang J, Wei X, et al. Preoperative ultrasound combined with routine blood tests in predicting the malignant risk of pancreatic cystic neoplasms. Cancer Biology & Medicine, 2022, 19(10): 1503-1516. https://doi.org/10.20892/j.issn.2095-3941.2022.0258

172

Views

1

Downloads

1

Crossref

1

Web of Science

1

Scopus

Altmetrics

Received: 09 May 2022
Accepted: 08 July 2022
Published: 03 November 2022
©2022 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License

Return